Royal Bank Of Canada Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its price target raised by Royal Bank Of Canada from $322.00 to $352.00 in a research report report published on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the medical research company’s stock.

CRL has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a report on Monday, August 10th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Finally, Zacks Research downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Monday. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $308.17.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $312.54 on Thursday. The stock has a 50-day simple moving average of $304.89 and a two-hundred day simple moving average of $224.59. Charles River Laboratories International has a 52-week low of $146.20 and a 52-week high of $379.63. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.04 and a current ratio of 1.41. The firm has a market capitalization of $14.92 billion, a PE ratio of 343.46, a P/E/G ratio of 3.04 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. During the same quarter last year, the company earned $2.43 earnings per share. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year. Analysts forecast that Charles River Laboratories International will post 11.41 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other news, Director James C. Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total value of $8,414,700.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at approximately $11,058,600. The trade was a 43.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of the business’s stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president owned 4,807 shares in the company, valued at $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 102,299 shares of company stock valued at $31,050,863. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CRL. Fifth Third Bancorp increased its position in Charles River Laboratories International by 24.1% in the third quarter. Fifth Third Bancorp now owns 22,112 shares of the medical research company’s stock worth $6,523,000 after purchasing an additional 4,299 shares during the last quarter. King Luther Capital Management Corp lifted its position in Charles River Laboratories International by 2.4% during the third quarter. King Luther Capital Management Corp now owns 55,083 shares of the medical research company’s stock valued at $16,250,000 after purchasing an additional 1,271 shares during the last quarter. New Mexico Educational Retirement Board lifted its position in Charles River Laboratories International by 330.0% during the third quarter. New Mexico Educational Retirement Board now owns 10,750 shares of the medical research company’s stock valued at $3,171,000 after purchasing an additional 8,250 shares during the last quarter. Maryland State Retirement & Pension System grew its stake in shares of Charles River Laboratories International by 440.4% in the 3rd quarter. Maryland State Retirement & Pension System now owns 14,395 shares of the medical research company’s stock worth $4,247,000 after buying an additional 11,731 shares in the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth $1,831,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: UBS raised its price target to $387 from $357 and maintained a Buy rating. UBS rating
• Positive Sentiment: Barclays increased its target to $375 from $330 with an Overweight rating, while RBC raised its target to $352 from $322 and kept its Outperform rating. Barclays rating RBC rating
• Positive Sentiment: CRL reported Q3 adjusted earnings of $3.09 per share, above estimates, and revenue of $982.7 million, also ahead of forecasts. Organic growth and margin expansion helped the company raise its 2026 outlook. Q3 earnings and outlook
• Negative Sentiment: Revenue fell 2.2% year over year. The market’s focus on softer sales despite earnings and revenue beats, as well as margin gains, appears to have tempered the positive results. Q3 market reaction
• Negative Sentiment: Zacks Research downgraded CRL from Strong Buy to Hold, adding a more cautious analyst view. Zacks Research rating

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.